Immunotech Laboratories Stock Analysis

IMMB Stock  USD 0.0001  0.00  0.000003%   
Below is the normalized historical share price chart for Immunotech Laboratories extending back to January 07, 2002. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Immunotech Laboratories stands at 0.0001, as last reported on the 4th of February, with the highest price reaching 0.0001 and the lowest price hitting 0.0001 during the day.
200 Day MA
0.0001
50 Day MA
0.0001
Beta
(125.21)
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
At present, Immunotech Laboratories' Debt To Equity is projected to slightly decrease based on the last few years of reporting. The current year's Long Term Debt To Capitalization is expected to grow to 0.24, whereas Net Debt To EBITDA is projected to grow to (5.79). With a high degree of financial leverage come high-interest payments, which usually reduce Immunotech Laboratories' Earnings Per Share (EPS).
Given that Immunotech Laboratories' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Immunotech Laboratories is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Immunotech Laboratories to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Immunotech Laboratories is said to be less leveraged. If creditors hold a majority of Immunotech Laboratories' assets, the Company is said to be highly leveraged.
The current year's Market Cap is expected to grow to about 54.1 K. The current year's Enterprise Value is expected to grow to about 2.3 M.
Immunotech Laboratories is overvalued with Real Value of 8.4E-5 and Hype Value of 1.0E-4. The main objective of Immunotech Laboratories stock analysis is to determine its intrinsic value, which is an estimate of what Immunotech Laboratories is worth, separate from its market price. There are two main types of Immunotech Laboratories' stock analysis: fundamental analysis and technical analysis.
The Immunotech Laboratories stock is traded in the USA on OTCCE Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Immunotech Laboratories' ongoing operational relationships across important fundamental and technical indicators.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunotech Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
For information on how to trade Immunotech Stock refer to our How to Trade Immunotech Stock guide.

Immunotech Stock Analysis Notes

The company has price-to-book (P/B) ratio of 0.01. Some equities with similar Price to Book (P/B) outperform the market in the long run. Immunotech Laboratories recorded a loss per share of 0.3. The entity had not issued any dividends in recent years. The firm had 1:100 split on the 26th of February 2009. Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus , acquired immune deficiency syndrome , hepatitis, and other immuno-related disorders. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Eco-Petroleum Solutions, Inc. Immunotech Labs is traded on OTC Exchange in the United States. To learn more about Immunotech Laboratories call the company at 626-538-4779 or check out https://www.immunotechlab.com.

Immunotech Laboratories Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Immunotech Laboratories' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Immunotech Laboratories or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Immunotech Laboratories generated a negative expected return over the last 90 days
Immunotech Laboratories has some characteristics of a very speculative penny stock
Net Loss for the year was (977.57 K) with profit before overhead, payroll, taxes, and interest of 0.
Immunotech Laboratories has a very weak financial position based on the latest SEC disclosures
Latest headline from news.google.com: AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering - GlobeNewswire

Immunotech Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 55.

Immunotech Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(1.09)(1.15)
Return On Capital Employed(0.08)(0.08)
Return On Assets(0.05)(0.06)
Return On Equity(0.09)(0.09)

Management Efficiency

As of February 4, 2026, Return On Tangible Assets is expected to decline to -1.15. The current year's Return On Capital Employed is expected to grow to -0.08. As of February 4, 2026, Return On Tangible Assets is expected to decline to -1.15. In addition to that, Intangibles To Total Assets is expected to decline to 0.71Immunotech Laboratories' management efficiency ratios could be used to measure how well Immunotech Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for Next Year
Book Value Per Share 0.01  0.01 
Tangible Book Value Per Share(0.01)(0.01)
Enterprise Value Over EBITDA(6.23)(5.92)
Price Book Value Ratio 0.01  0.01 
Enterprise Value Multiple(6.23)(5.92)
Price Fair Value 0.01  0.01 
Enterprise Value2.2 M2.3 M
Immunotech Laboratories has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta
(125.21)

Technical Drivers

Immunotech Laboratories technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Immunotech Laboratories Price Movement Analysis

Execute Study
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Immunotech Laboratories middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Immunotech Laboratories. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Immunotech Laboratories Financial Rating

Immunotech Laboratories financial ratings play a critical role in determining how much Immunotech Laboratories have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Immunotech Laboratories' borrowing costs.
Piotroski F Score
1
Very WeakView

Immunotech Laboratories Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Immunotech Laboratories uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Immunotech Laboratories Debt Ratio

    
  20.0   
It appears most of the Immunotech Laboratories' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Immunotech Laboratories' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Immunotech Laboratories, which in turn will lower the firm's financial flexibility.

Immunotech Net Debt To E B I T D A

Net Debt To E B I T D A

(5.79)

At present, Immunotech Laboratories' Net Debt To EBITDA is projected to slightly decrease based on the last few years of reporting.

About Immunotech Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunotech Laboratories prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunotech shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Immunotech Laboratories. By using and applying Immunotech Stock analysis, traders can create a robust methodology for identifying Immunotech entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(12.56)(13.19)
Operating Profit Margin(24.94)(26.18)
Net Loss(12.67)(13.30)

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Immunotech Laboratories to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Crypto Correlations Now

   

Crypto Correlations

Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
All  Next Launch Module

Complementary Tools for Immunotech Stock analysis

When running Immunotech Laboratories' price analysis, check to measure Immunotech Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunotech Laboratories is operating at the current time. Most of Immunotech Laboratories' value examination focuses on studying past and present price action to predict the probability of Immunotech Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunotech Laboratories' price. Additionally, you may evaluate how the addition of Immunotech Laboratories to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Stocks Directory
Find actively traded stocks across global markets
Fundamental Analysis
View fundamental data based on most recent published financial statements